melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery

Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 
in vivo models melior discovery theratrace

 

theraTRACE phenotypic screening melior discovery

 

Melior Pharmaceuticals drug development drug repostioning drug rescuing

 

 

Recent Studies Using   Phenotypic Screening:


Phenotypic screening identifies Axl kinase as a nega...

Related Articles Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. Lab Invest. 2017 May 29;: Authors: Fujino N, Kubo H, Maciewicz RA Abstract Loss of epithelial barrier integrity is implic...

Small-molecule phenotypic screening with stem cells.

Related Articles Small-molecule phenotypic screening with stem cells. Nat Chem Biol. 2017 May 17;13(6):560-563 Authors: Ursu A, Schöler HR, Waldmann H PMID: 28514421 [PubMed - in process]

Application of Combination High-Throughput Phenotypi...

Related Articles Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs. Med Res Rev. 2017 May 16;: Authors: Isgut M, Rao M, Yang C, Subrahmany...

 

David Swinney and Jason Anthony Phenotypic Screening

Most new medicines were discovered by phenotypic screeing

See Nature Reviews Drug Discovery article by David C. Swinney & Jason Anthony

Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some [...]

Read Full Article

 

              

 

             

 

                 

 

     Melior Discovery theraTRACE phenotypic screening in vivo pharmacology drug repositioning

Melior Discovery: theraTRACE® Phenotypic Screening Platform


Melior Discovery's theraTRACE® phenotypic screening platform provides a cost-effective means for evaluating a repositioning candidate through a broad array of in vivo models of disease.

 

Melior's standard platform is designed to assess compounds across a wide therapeutic spectrum in an unbiased fashion (i.e. this is a non-hypothesis-driven approach).  By evaluating compounds through approximately 40 different animal models representing 14 broad therapeutic areas, Melior is able to uncover therapeutic efficacy that is otherwise unpredicted and expected by other means

 

Years of experience with the models incorporated into theraTRACE® have allowed Melior to multiplex the models, thereby allowing this work to be done for a fraction of the cost compared to running the models independent of one another, yet without comprimising the quality of the models in any way.  Typically, one or more compounds can be evaluated across a full suite of 40 models in about 10 weeks.

 

If you are interested in learning more about the theraTRACE® phenotypic screening platform, please contact bizdev@meliordiscovery.com to start the conversation.


Multiplexing drug repositioning

         Multiplexing in vivo models in vivo pharmacology

Multiplexing

Multiplexing

Multiplexing and Drug Repositioning

 

 

 

 



 

home theraTRACE Melior Pharmaceuticals